Limits...
Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011.

Armitage J, Cuzick J, Elwood P, Longley M, Perkins A, Spencer K, Turner H, Porch S, Lyness S, Kennedy J, Henderson G - Ecancermedicalscience (2012)

Bottom Line: On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people.The meeting was supported by Bayer Pharma AG and Novacyl.

View Article: PubMed Central - PubMed

Affiliation: Professor of Clinical Trials and Epidemiology, Clinical Trials Surveillance Unit, Oxford.

ABSTRACT
On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people. The meeting was supported by Bayer Pharma AG and Novacyl.

No MeSH data available.


Related in: MedlinePlus

Gastro-intestinal bleed (or other major extracranial bleed) in primary prevention trials.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
getmorefigures.php?uid=PMC3298410&req=5

f6-can-6-245: Gastro-intestinal bleed (or other major extracranial bleed) in primary prevention trials.

Mentions: There have been six large studies of primary prevention with aspirin, with approximately 660,000 person-years of follow-up in a population of 95,000 largely healthy people, of whom about one-third were over 65 years old [1]. The risks of stroke and vascular death were not significantly reduced; the risk of coronary heart disease was significantly reduced by 18 per cent but there was no reduction in coronary deaths; combining these endpoints, the overall risk reduction of 12 per cent was statistically significant (Figure 2). Against this, the overall risk of gastrointestinal or other extracranial bleeding event was increased by 54 per cent (Figure 3), although it should be noted that data on bleeding events were not collected with care. Importantly, the risk of bleeding correlated with the risk of coronary events, suggesting that people at greatest risk from heart disease were also at increased risk from the adverse effects of aspirin.


Aspirin for the older person: report of a meeting at the Royal Society of Medicine, London, 3rd November 2011.

Armitage J, Cuzick J, Elwood P, Longley M, Perkins A, Spencer K, Turner H, Porch S, Lyness S, Kennedy J, Henderson G - Ecancermedicalscience (2012)

Gastro-intestinal bleed (or other major extracranial bleed) in primary prevention trials.
© Copyright Policy - open-access
Related In: Results  -  Collection

License 1 - License 2
Show All Figures
getmorefigures.php?uid=PMC3298410&req=5

f6-can-6-245: Gastro-intestinal bleed (or other major extracranial bleed) in primary prevention trials.
Mentions: There have been six large studies of primary prevention with aspirin, with approximately 660,000 person-years of follow-up in a population of 95,000 largely healthy people, of whom about one-third were over 65 years old [1]. The risks of stroke and vascular death were not significantly reduced; the risk of coronary heart disease was significantly reduced by 18 per cent but there was no reduction in coronary deaths; combining these endpoints, the overall risk reduction of 12 per cent was statistically significant (Figure 2). Against this, the overall risk of gastrointestinal or other extracranial bleeding event was increased by 54 per cent (Figure 3), although it should be noted that data on bleeding events were not collected with care. Importantly, the risk of bleeding correlated with the risk of coronary events, suggesting that people at greatest risk from heart disease were also at increased risk from the adverse effects of aspirin.

Bottom Line: On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people.The meeting was supported by Bayer Pharma AG and Novacyl.

View Article: PubMed Central - PubMed

Affiliation: Professor of Clinical Trials and Epidemiology, Clinical Trials Surveillance Unit, Oxford.

ABSTRACT
On November 23rd 2011, the Aspirin Foundation held a meeting at the Royal Society of Medicine in London to review current thinking on the potential role of aspirin in preventing cardiovascular disease and reducing the risk of cancer in older people. The meeting was supported by Bayer Pharma AG and Novacyl.

No MeSH data available.


Related in: MedlinePlus